Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)’s stock price has gone rise by 11.37 in comparison to its previous close of 7.52, however, the company has experienced a 16.16% increase in its stock price over the last five trading days. zacks.com reported 2024-11-07 that Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.09 per share a year ago.
Is It Worth Investing in Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Right Now?
Moreover, the 36-month beta value for AUPH is 1.37. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AUPH is 128.68M and currently, short sellers hold a 5.59% of that float. On November 07, 2024, AUPH’s average trading volume was 1.17M shares.
AUPH’s Market Performance
AUPH stock saw an increase of 16.16% in the past week, with a monthly gain of 24.07% and a quarterly increase of 55.09%. The volatility ratio for the week is 3.20%, and the volatility levels for the last 30 days are 2.98% for Aurinia Pharmaceuticals Inc (AUPH). The simple moving average for the last 20 days is 15.39% for AUPH’s stock, with a simple moving average of 38.24% for the last 200 days.
Analysts’ Opinion of AUPH
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see AUPH reach a price target of $25, previously predicting the price at $34. The rating they have provided for AUPH stocks is “Overweight” according to the report published on May 05th, 2022.
Oppenheimer gave a rating of “Outperform” to AUPH, setting the target price at $31 in the report published on December 10th of the previous year.
AUPH Trading at 17.99% from the 50-Day Moving Average
After a stumble in the market that brought AUPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.67% of loss for the given period.
Volatility was left at 2.98%, however, over the last 30 days, the volatility rate increased by 3.20%, as shares surge +21.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +27.99% upper at present.
During the last 5 trading sessions, AUPH rose by +17.34%, which changed the moving average for the period of 200-days by +7.36% in comparison to the 20-day moving average, which settled at $7.26. In addition, Aurinia Pharmaceuticals Inc saw -6.84% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AUPH starting from Habig Scott Michael, who sale 18,249 shares at the price of $5.31 back on Aug 06 ’24. After this action, Habig Scott Michael now owns 456,338 shares of Aurinia Pharmaceuticals Inc, valued at $96,902 using the latest closing price.
Balakrishnan Brinda, the Director of Aurinia Pharmaceuticals Inc, sale 520 shares at $5.74 during a trade that took place back on May 21 ’24, which means that Balakrishnan Brinda is holding 17,523 shares at $2,985 based on the most recent closing price.
Stock Fundamentals for AUPH
Current profitability levels for the company are sitting at:
- -0.23 for the present operating margin
- 0.86 for the gross margin
The net margin for Aurinia Pharmaceuticals Inc stands at -0.24. The total capital return value is set at -0.11. Equity return is now at value -13.30, with -9.39 for asset returns.
Based on Aurinia Pharmaceuticals Inc (AUPH), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -0.01. The debt to equity ratio resting at 0.24. The interest coverage ratio of the stock is -9.3.
Currently, EBITDA for the company is -71.67 million with net debt to EBITDA at -2.2. When we switch over and look at the enterprise to sales, we see a ratio of 6.05. The receivables turnover for the company is 8.11for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.33.
Conclusion
To wrap up, the performance of Aurinia Pharmaceuticals Inc (AUPH) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
